Free tool
FAERS Monitor: Quillivant Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202100 or its brand name (Quillivant Xr, Methylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
9,150
Serious
4,614
50% of reports
Hospitalization
1,777
Death reported
445
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,555
- off label use536
- headache467
- anxiety419
- fatigue390
- nausea388
- decreased appetite380
- insomnia336
- toxicity to various agents334
- disturbance in attention320
- somnolence315
- product substitution issue298
- abnormal behaviour291
- agitation290
- drug abuse287
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 18 |
| 2010 | 14 |
| 2011 | 18 |
| 2012 | 69 |
| 2013 | 291 |
| 2014 | 380 |
| 2015 | 809 |
| 2016 | 672 |
| 2017 | 729 |
| 2018 | 847 |
| 2019 | 570 |
| 2020 | 400 |
| 2021 | 459 |
| 2022 | 664 |
| 2023 | 850 |
| 2024 | 788 |
| 2025 | 807 |
| 2026 | 750 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,009 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abnormal behaviourSignal | 291 | 17.0 | 15.2 | 4,343 |
| disturbance in attentionSignal | 320 | 13.7 | 12.3 | 3,746 |
| product substitution issueSignal | 298 | 12.0 | 10.7 | 2,973 |
| agitationSignal | 290 | 9.1 | 8.1 | 2,085 |
| drug abuseSignal | 287 | 7.9 | 7.1 | 1,737 |
| toxicity to various agentsSignal | 334 | 4.6 | 4.1 | 930 |
| decreased appetiteSignal | 380 | 3.8 | 3.4 | 776 |
| somnolenceSignal | 315 | 3.6 | 3.2 | 594 |
| anxietySignal | 419 | 3.4 | 3.1 | 711 |
| insomniaSignal | 336 | 2.9 | 2.6 | 422 |
| drug ineffectiveSignal | 1,555 | 2.7 | 2.6 | 1,792 |
| headache | 467 | 1.7 | 1.6 | 142 |
| off label use | 536 | 1.4 | 1.3 | 65 |
| fatigue | 390 | 1.2 | 1.0 | 8 |
| nausea | 388 | 1.1 | 1.0 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.